Clinical Trial Results:
A RANDOMISED, PLACEBO-CONTROLLED, CROSSOVER STUDY TO EVALUATE THE EFFECT OF LINACLOTIDE ON COLONIC MOTILITY ASSESSED WITH INTRALUMINAL COLONIC MANOMETRY IN HEALTHY SUBJECTS
Summary
|
|
EudraCT number |
2013-004939-73 |
Trial protocol |
BE |
Global end of trial date |
28 Jan 2015
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
28 Dec 2024
|
First version publication date |
28 Dec 2024
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
LINACLOTIDEPLACEBO
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
TARGID UZLEUVEN KULEUVEN
|
||
Sponsor organisation address |
Herestraat 49, Leuven, Belgium, 3000
|
||
Public contact |
Jan Tack, KULEUVEN, 0032 16344225, jan.tack@kuleuven.be
|
||
Scientific contact |
Jan Tack, KULEUVEN, 0032 16344225, jan.tack@kuleuven.be
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
07 Oct 2024
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
28 Jan 2015
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
28 Jan 2015
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
to evaluate the effects of linaclotideas compared to placebo on motility index and on the number of colonic high amplitude propagated contractions (HAPCs) during a 8-hour intraluminal manometry in healthy subjects.
|
||
Protection of trial subjects |
healthy volunteers. sedation during colonoscopy
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
15 Jan 2014
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Belgium: 10
|
||
Worldwide total number of subjects |
10
|
||
EEA total number of subjects |
10
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
10
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||
Recruitment
|
||||||||||
Recruitment details |
healthy subjects | |||||||||
Pre-assignment
|
||||||||||
Screening details |
healthy subjects with a normal bowel habit No diagnosis of organic or functional gastrointestinal disease. no abdominal surgery other than appendectomy. No intake of laxatives or other medications. | |||||||||
Period 1
|
||||||||||
Period 1 title |
overall period
|
|||||||||
Is this the baseline period? |
Yes | |||||||||
Allocation method |
Randomised - controlled
|
|||||||||
Blinding used |
Double blind | |||||||||
Roles blinded |
Subject, Investigator | |||||||||
Arms
|
||||||||||
Are arms mutually exclusive |
No
|
|||||||||
Arm title
|
linaclotide | |||||||||
Arm description |
After 90 min of basal recording, linaclotide 290 µg was administered orally in double-blind, randomized, cross-over fashion, and the recording continued for 180 min before and after a standardized meal oral intake of 290 µg linaclotide in a single administration, together with 125mL of water; | |||||||||
Arm type |
Active comparator | |||||||||
Investigational medicinal product name |
linaclotide
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Capsule
|
|||||||||
Routes of administration |
Oral use
|
|||||||||
Dosage and administration details |
oral intake of 290 µg linaclotide in a single administration, together with 125mL of water;
|
|||||||||
Arm title
|
placebo | |||||||||
Arm description |
After 90 min of basal recording, placebo was administered orally in double-blind, randomized, cross-over fashion, and the recording continued for 180 min before and after a standardized meal oral intake of placebo, consisting in an empty capsule in a single oral administration, together with 125mL of water | |||||||||
Arm type |
Placebo | |||||||||
Investigational medicinal product name |
placebo
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Capsule
|
|||||||||
Routes of administration |
Oral use
|
|||||||||
Dosage and administration details |
On the first day of each treatment period, after a 12-h fasting period, all subjects were admitted to the Motility Unit. Bowel preparation was performed through a tap water enema. Oral intake of placebo, consisting in an empty capsule in a single oral administration, together with 125mL of water.
|
|||||||||
|
|
|||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||
Reporting group title |
overall period
|
||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
linaclotide
|
||
Reporting group description |
After 90 min of basal recording, linaclotide 290 µg was administered orally in double-blind, randomized, cross-over fashion, and the recording continued for 180 min before and after a standardized meal oral intake of 290 µg linaclotide in a single administration, together with 125mL of water; | ||
Reporting group title |
placebo
|
||
Reporting group description |
After 90 min of basal recording, placebo was administered orally in double-blind, randomized, cross-over fashion, and the recording continued for 180 min before and after a standardized meal oral intake of placebo, consisting in an empty capsule in a single oral administration, together with 125mL of water |
|
|||||||||||||||||||||||||||||||
End point title |
Colonic motility index | ||||||||||||||||||||||||||||||
End point description |
After 90 min of basal recording, linaclotide 290 µg or placebo were administered orally in double-blind, randomized, cross-over fashion, and the recording continued for 180 min before and after a standardized meal. Colonic motility index of the right, left colon and rectum, expressed as ratio of the baseline value was compared between treatments by means of a mixed models analysis.
|
||||||||||||||||||||||||||||||
End point type |
Primary
|
||||||||||||||||||||||||||||||
End point timeframe |
After 90 min of basal recording, linaclotide 290 µg or placebo were administered orally in double-blind, randomized, cross-over fashion, and the recording continued for 180 min before and after a standardized meal.
|
||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||
Notes [1] - the tracing displayed too many artifacts to be properly evaluated and therefore be reliable |
|||||||||||||||||||||||||||||||
Statistical analysis title |
Colonic motility index | ||||||||||||||||||||||||||||||
Statistical analysis description |
Colonic motility index (MI; averaged every 15 min in the right and left colon and in the rectum, and expressed as ratio of the baseline value) of four periods (pre-prandial, first, second, and third hour after the meal) was compared between treatments by means of a mixed models analysis with post hoc t tests and Bonferroni correction.
|
||||||||||||||||||||||||||||||
Comparison groups |
placebo v linaclotide
|
||||||||||||||||||||||||||||||
Number of subjects included in analysis |
19
|
||||||||||||||||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||||||||||||||||
Analysis type |
superiority | ||||||||||||||||||||||||||||||
P-value |
≤ 0.05 [2] | ||||||||||||||||||||||||||||||
Method |
Mixed models analysis | ||||||||||||||||||||||||||||||
Confidence interval |
|||||||||||||||||||||||||||||||
Notes [2] - Baseline MI did not differ between treatments in the right, left colon and rectum. At mixed models analysis, no treatment effect was found on the ratio of the baseline value of colonic MI in any of the region of the colon |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
For each individual, corresponds to timeframe of study participation (from signing of informed consent until last visit)
|
||
Assessment type |
Non-systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
MedDRA | ||
Dictionary version |
23
|
||
Frequency threshold for reporting non-serious adverse events: 5% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: No adverse events happened during this study protocol |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |